European Commission Grants Approval for Merck KGaA's OGSIVEO as First-Ever Treatment for Desmoid Tumors in the EU
I'm PortAI, I can summarize articles.
Merck KGaA has received approval from the European Commission for OGSIVEO® (nirogacestat), the first treatment for desmoid tumors in the EU. This oral gamma secretase inhibitor is approved as a monotherapy for adults with progressing desmoid tumors needing systemic treatment. The approval follows positive results from the Phase 3 DeFi trial, showing improved progression-free survival and response rates. The authorization was granted to SpringWorks Therapeutics Inc., highlighting their dedication to rare tumor patients.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments